TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
←

stan druckenmiller

T1 · high-signal investor

Stan Druckenmiller is a legendary investor who ran Duquesne Capital for 30 years and managed George Soros's Quantum Fund, famously breaking the Bank of England in 1992. He now runs a family office and is known for macro investing across asset classes with concentrated positions.

3 calls·3 names·33% bull·last heard 2 years ago·In Good Company with Nicolai Tangen
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1sthigh conviction
$US10YUS 10-Year Treasuryposition

Druckenmiller short 10-year Treasuries at 25% NAV betting on inflation resurgence and failed auction risk

Shorting 10-year Treasury equivalents (25% of NAV) because Fed cutting 50bps into tight financial conditions, gold highs, roaring equities, and 7% deficit at full employment risks 1970s-style inflation rebound that could force rate hikes and failed auctions.

In Good Company with Nicolai Tangen2024-11episode →
2ndmedium conviction
$NVDANvidia

Druckenmiller bought Nvidia early on AI thesis but sold at $800-900 as valuation exceeded $2T

Bought Nvidia as picks-and-shovels AI play after young analysts flagged engineer shift from crypto to AI; sold when market cap surpassed $2T viewing it as cyclical semiconductor at excessive valuation, though acknowledges CUDA moat and staying power.

In Good Company with Nicolai Tangen2024-11episode →
3rdmedium conviction
$LLYEli Lilly

Druckenmiller profited from Eli Lilly's GLP-1 obesity drugs viewing it as razor-blade recurring revenue model

Identified anti-obesity drugs early as structural winner because American consumers want weight loss without effort and must stay on drug indefinitely to maintain results, creating chronic recurring revenue like razor blades.

In Good Company with Nicolai Tangen2024-11episode →

most discussed · click a bar to filter

  • $NVDA
  • $US10Y
  • $LLY

recurring themes

  • Macro & Rates1
  • AI Infrastructure1
  • AI Economics & Business Models1
  • GLP-1 & Metabolic Drugs1
  • Public Markets & Valuation1
3 total
$NVDA
···
Nvidia
MEDstan druckenmiller·In Good Company with Nicolai Tangen·2 years ago·Stan Druckenmiller | Podcast | In Good Company | Norges Bank Investment Management
Druckenmiller bought Nvidia early on AI thesis but sold at $800-900 as valuation exceeded $2T
Bought Nvidia as picks-and-shovels AI play after young analysts flagged engineer shift from crypto to AI; sold when market cap surpassed $2T viewing it as cyclical semiconductor at excessive valuation, though acknowledges CUDA moat and staying power.
"I bought a pretty good chunk of it and then like a month later chaty PT happened it was just total luck I had no idea caty p but the AI drum around here was big enough and the sto…"
11:52
$US10Y
···
US 10-Year Treasury
HIGHstan druckenmiller·In Good Company with Nicolai Tangen·2 years ago·Stan Druckenmiller | Podcast | In Good Company | Norges Bank Investment Management· position
Druckenmiller short 10-year Treasuries at 25% NAV betting on inflation resurgence and failed auction risk
Shorting 10-year Treasury equivalents (25% of NAV) because Fed cutting 50bps into tight financial conditions, gold highs, roaring equities, and 7% deficit at full employment risks 1970s-style inflation rebound that could force rate hikes and failed auctions.
"I'm short bonds I'm not like mega short I I actually had good timing for once I shorted them literally the day the FED cut um it's been kind of an easy ride since then I should ha…"
9:18
$LLY
···
Eli Lilly
MEDstan druckenmiller·In Good Company with Nicolai Tangen·2 years ago·Stan Druckenmiller | Podcast | In Good Company | Norges Bank Investment Management
Druckenmiller profited from Eli Lilly's GLP-1 obesity drugs viewing it as razor-blade recurring revenue model
Identified anti-obesity drugs early as structural winner because American consumers want weight loss without effort and must stay on drug indefinitely to maintain results, creating chronic recurring revenue like razor blades.
"you were also early into the anti-obesity drug producers oh that was easy I mean I don't know what it's like in Norway but in America yeah if you go to Disney World everything and…"
14:22
9
Macro & Ratesrisk
Druckenmiller warns Fed cutting too early risks 1970s-style inflation resurgence
Financial conditions easing post-Fed cut, tight credit spreads, gold highs, equities roaring mirror 1970s pattern where inflation fell then rebounded; deficit spending at 7% GDP with full employment unsustainable, risk of failed Treasury auction or inflation rebound forcing rate hikes.
8
AI Infrastructuretailwind
Druckenmiller: AI model layer capex unsustainable, applications layer the real opportunity
Hyperscalers spending massively on AI models but multiple players will produce similar results, creating winner-take-most not winner-take-all; real value will emerge in unforeseen applications like internet in 2001, so investors should be patient for application layer.
8
AI Economics & Business Modelstailwind
Druckenmiller: AI investment playbook mirrors internet 2001 - believe in trend, wait for application layer
Just as early internet believers could have waited for Uber/Facebook applications, AI investors should be patient for unforeseen killer apps rather than chasing infrastructure layer where capex is massive and differentiation low.
7
GLP-1 & Metabolic Drugstailwind
Druckenmiller: GLP-1 drugs a razor-blade business model driven by American psychology
Anti-obesity drugs like Lilly's tirzepatide create chronic recurring revenue because patients regain weight after stopping; understood early by observing American consumer behavior at Disney World.
6
Public Markets & Valuationmixed
Druckenmiller: Narrow market leadership a yellow light, not yet red for bear market
Market breadth narrowing is necessary condition for bear market but not sufficient; financials broadening provides some offset; current conditions warrant caution but not outright bearishness.